Safety and Efficacy of PCSK9 Inhibitor Treatment in Heart Transplant Patients

Transplantation. 2019 Mar;103(3):e58. doi: 10.1097/TP.0000000000002520.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Biopsy
  • Cardiomyopathy, Dilated / surgery*
  • Heart Failure / surgery*
  • Heart Transplantation / methods*
  • Humans
  • Hyperlipidemias
  • Immunocompromised Host
  • Immunosuppression Therapy
  • Male
  • Middle Aged
  • PCSK9 Inhibitors*
  • Patient Safety
  • Prognosis
  • Treatment Outcome
  • Vascular Diseases / metabolism
  • Vascular Diseases / prevention & control

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • evolocumab